Biogen’s ALS Drug Qalsody Price Tag Set at Over $14,000

May 3, 2023

Biogen has announced that its new amyotrophic lateral sclerosis (ALS) drug Qalsody will launch with a list price of $14,230 per dose. The drug was just granted accelerated approval by the US Food and Drug Administration (FDA) based on data showing that it reduced levels of neurofilament, a hallmark of the drug that drives disease pathology.

According to Nicole DeFeudis, “Biogen said last week that it would price Qalsody “within a range comparable to other recently launched ALS treatments.” Amylyx Pharmaceuticals’ Relyvrio, approved in September, is priced at $158,000 per year. Two prior drugs have been approved for ALZ: riluzole in the 1990s and edaravone in 2017, the latter of which can cost up to $171,000 for the oral formulation.”

To read more, click here.